Advertisement

Springer Seminars in Immunopathology

, Volume 21, Issue 1, pp 77–90 | Cite as

Treatments targeting the T cell receptor (TCR): effects of TCR peptide-specific T cells on activation, migration, and encephalitogenicity of myelin basic protein-specific T cells

  • Halina Offner
  • Ray Jacobs
  • Bruce F. BeboJr.
  • Arthur A. Vandenbark
Article

Keywords

Internal Medicine Cell Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alvord EC Jr (1984) Species-restricted encephalitogenic determinants. In: Alvord EC Jr, Kies MW, Suckling AJ (eds) Experimental allergic encephalomyelitis: a useful model for multiple sclerosis. Liss, New York, pp 523Google Scholar
  2. 2.
    Ben-Nun A, Wekerle H, Cohen IR (1981) The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 11: 195Google Scholar
  3. 3.
    Bernaud E, Reshef T, Vandenbark AA, Offner H, Fritz R, Chou CH, Bernard D, Cohen IR (1986) Experimental autoimmune encephalomyelitis mediated by T lymphocyte lines: genotype of antigen presenting cells influences immunodominant epitope of basic protein. J Immunol 136: 511Google Scholar
  4. 4.
    Bourdette DN, Vainiene M, Morrison WJ, Jones R, Turner J, Hashim GA, Vandenbark AA, Offner H (1991) Myelin basic protein specific T cell lines and clones derived from the central nervous system of rats with experimental autoimmune encephalomyelitis only recognize encephalitogenic epitopes. J Neurosci Res 30: 308Google Scholar
  5. 5.
    Clayton JP, Gammon GM, Ando DG, Kono DH, Hood L, Sercarz EE (1989) Peptide-specific prevention of experimental allergic encephalomyelitis: neonatal tolerance induced to the dominant T cell determinant of myelin basic protein. J Exp Med 169:1681Google Scholar
  6. 6.
    Critchfield JM, Racke MK, Zuniga-Pflucker JC, Cannella B, Raine CS, Goverman J, Lenardo MJ (1994) T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263: 1139Google Scholar
  7. 7.
    Deibler GE, Martenson RE, Kies MW (1972) Large-scale preparation of myelin basic protein from central nervous system tissue of several mammalian species. Prep Biochem 2: 139Google Scholar
  8. 8.
    De Magistris MT, Alexander J, Coggeshall M, et al (1992) Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 68: 625Google Scholar
  9. 9.
    Evavold BD, Sloan LJ, Allen PM (1993) Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunol Today 14: 602Google Scholar
  10. 10.
    Falb D, Briner TJ, Sunshine GH, et al (1996) Peripheral tolerance in T cell receptor-transgenic mice: Evidence for T cell anergy. Eur J Immunol 26:130Google Scholar
  11. 11.
    Falcioni F, Vidovic D, Ward ES, Bolin D, Singh G, Shah H, Ober B, Nagy ZA (1995) Self tolerance to T cell receptor VB sequences. J Exp Med 182: 249Google Scholar
  12. 12.
    Gaur A, Wiers B, Liu A, Rothbard J, Fathman CG (1992) Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 258: 1491Google Scholar
  13. 13.
    Gautam AM, Pearson CI, Smilek DE, Steinman L, McDevitt HO (1992) A polyalanine peptide with only five native myelin basic protein residues induces autoimmune encephalomyelitis. J Exp Med 176: 605Google Scholar
  14. 14.
    Gershon RK, Kondo K (1971) Infectious immunological tolerance. Immunology 21:903Google Scholar
  15. 15.
    Gregerson DS, Orbitsch WF, Donoso LA (1993) Oral tolerance in experimental autoimmune uveoretinitis: distinct mechanisms of resistance are induced by low dose vs high dose feeding protocols. J Immunol 151:5751Google Scholar
  16. 16.
    Heber-Katz E, Acha-Orbea H (1989) The V-region disease hypothesis: evidence from autoimmune encephalomyelitis. Immunol Today 10: 164Google Scholar
  17. 17.
    Hickey WF, Hsu BL, Kimura H (1991) T-lymphocyte entry into the central nervous system. J Neurosci Res 28:254Google Scholar
  18. 18.
    Howell MD, Winters ST, Olee T, Powell HC, Carlo DJ, Brostoff SW (1989) Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 246: 668Google Scholar
  19. 19.
    Jenkins MK, Schwartz RH (1994) Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 165: 302Google Scholar
  20. 20.
    Karin N, Mitchell DJ, Brocke S, Ling N, Steinman L (1994) Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production. J Exp Med 180: 2227Google Scholar
  21. 21.
    Karpus WJ, Swanborg RH (1991) CD4 suppressor cells inhibit the function of effector cells of experimental autoimmune encephalomyelitis through a mechanism involving transform growth factor-beta. J Immunol 146: 1163Google Scholar
  22. 22.
    Kearney ER, Pape KA, Loh DY, Jenkins MK (1994) Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1:327Google Scholar
  23. 23.
    Khoury SJ, Gallon L, Chen W, Betres K, Russell ME, Hancock WW, Carpenter CB, Sayegh MH, Weiner HL (1995) Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo. J Exp Med 182: 357Google Scholar
  24. 24.
    Kuhrober A, Schirmbeck R, Reimann J (1994) Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL. Eur J Immunol 24:1172Google Scholar
  25. 25.
    Kumar V, Urban JL, Horvath SJ, Hood L (1990) Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T-cell activation, major histocompatibility complex binding, and ability to block experimental allergic encephalomyelitis. Proc Natl Acad Sci USA 87: 1337Google Scholar
  26. 26.
    Kumar V, Stellrecht K, Sercarz E (1996) Inactivation of T cell receptor peptide-specific CD4 regulatory T cells induces chronic experimental autoimmune encephalomyelitis (EAE). J Exp Med 184: 1609Google Scholar
  27. 27.
    Lider O, Santos LMB, Lee CSY, Higgins PJ, Weiner HL (1989) Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. II. Suppression of disease and in vitro immune responses is mediated by antigen-specific CD8+ T lymphocytes. J Immunol 142: 748Google Scholar
  28. 28.
    Linington C, Berger T, Peny L, et al. (1993) T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol 23:1364Google Scholar
  29. 29.
    Mattingly JA, Waksman BH (1978) Immunologic suppression after oral administration of antigen. I. Specific suppressor cells formed in rat Peyer's patches after oral administration of sheep erythrocytes and their systemic migration. J Immunol 121:1878Google Scholar
  30. 30.
    Metzler B, Wraith DC (1993) Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol 5:1159Google Scholar
  31. 31.
    Miller A, Zhang ZJ, Sobel RA, AI-Sabbagh A, Weiner HL (1993) Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. VI. Suppression of adoptively transferred disease and differential effects of oral vs. intravenous tolerization. J Neuroimmunol 46: 73Google Scholar
  32. 32.
    Miller SD, Karpus WJ (1994) The immunopathogenesis and regulation of T-cell-mediated demyelinating diseases. Immunol Today 15: 356Google Scholar
  33. 33.
    Moudgil KD, Sercarz EE (1994) The T cell repertoire against cryptic self determinants and its involvement in autoimmunity and cancer. Clin Immunol Immunopathol 73: 283Google Scholar
  34. 34.
    Nihira S-I, Falcioni F, Juretic A, Bolin D, Nagy ZA (1996) Induction of class II major histocompatibility complex blockade as well as T cell tolerance by peptides administered in soluble form. Eur J Immunol 26:1736Google Scholar
  35. 35.
    Offner H, Hashim GA, Vandenbark AA (1991) T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science 251:430Google Scholar
  36. 36.
    Offner H, Buenafe AC, Vainiene M, Celnik B, Weinberg AD, Gold DP, Hashim G, Vandenbark AA (1993) Where, when and how to detect biased expression of disease-relevant VB genes in rats with experimental autoimmune encephalomyelitis. J Immunol 151: 506Google Scholar
  37. 37.
    Offner H, Hashim G, Chou YK, Bourdette D, Vandenbark AA (1993) Prevention, suppression, and treatment of EAE with a synthetic T cell receptor V region peptide. In: Alt FW, Vogel MG (eds) Molecular mechanisms of immunological self-recognition. Academic Press, New York, pp 199–230Google Scholar
  38. 38.
    Offner H, Vainiene M, Celnik B, Weinberg AD, Buenafe A, Vandenbark AA (1994) Co-culture of TCR peptide-specific T cells with basic protein-specific T cells inhibits proliferation, IL-3 mRNA, and transfer of experimental autoimmune encephalomyelitis. J Immunol 153: 4988Google Scholar
  39. 39.
    Offner H, Hashim GA, Vandenbark AA (1994) Immunity to T cell receptor peptides: theory and applications. Regul Pept 51:77Google Scholar
  40. 40.
    Offner H, Adlard K, Bebo BF Jr, Schuster J, Burrows GG, Buenafe AC, Vandenbark AA (1998) Vaccination with BV8S2 protein amplifies TCR specific regulation and protection against experimental autoimmune encephalomyelitis in TCR BV8S2 transgenic mice. J Immunol 161:2178Google Scholar
  41. 41.
    Peterson JD, Karpus WJ, Clatch RJ, Miller SD (1993) Split tolerance to Th1 and Th2 cells in tolerance to Theiler's murine encephalomyelitis virus. Eur J Immunol 23:46Google Scholar
  42. 42.
    Qin Y, Sun D, Goto M, Meyermann R, Wekerle H (1989) Resistance to experimental autoimmune encephalomyelitis induced by neonatal tolerization to myelin basic protein: clonal elimination vs. regulation of autoaggressive lymphocytes. Eur J Immunol 19: 373Google Scholar
  43. 43.
    Quill H, Schwartz RH (1987) Stimulation of normal inducer T cell clones with antigen presented by purified la molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness. J Immunol 138: 3704Google Scholar
  44. 44.
    Ransohoff RM, Hamilton TA, Tani M, Stoler MH, Shick HE, Major JA, Estes ML, Thomas DM, Tuohy VK (1993) Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J 7: 592Google Scholar
  45. 45.
    Selmaj KW, Raine CS (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23:339Google Scholar
  46. 46.
    Sharma SD, Nag B, Su X-M, Green D, Spack E, Clark BR, Sriram S (1991) Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class Il major histocompatibility complex-peptide complexes. Proc Natl Acad Sci USA 88: 11465Google Scholar
  47. 47.
    Singh RR, Hahn BH, Sercarz EE (1996) Neonatal peptide exposure can prime T cells and, upon subsequent immunization, induce their immune deviation: implications for antibody vs. T cell-mediated autoimmunity. J Exp Med 183:1613Google Scholar
  48. 48.
    Spack EG, McCutcheon M, Corbelletta N, Nag B, Passmore D, Sharma SD (1995) Induction of tolerance in experimental autoimmune myasthenia gravis with solubilized MHC class II: acetylcholine receptor peptide complexes. J Autoimmun 8:787Google Scholar
  49. 49.
    Streilein JW, Ksander BP, Taylor AW (1997) Immune deviation in relation to ocular immune privilege. J Immunol 158:3557Google Scholar
  50. 50.
    Strejan GH, St. Louis J (1990) Suppression of experimental allergic encephalomyelitis by MBP-liposomes: a comparison. Cell Immunol 127:284Google Scholar
  51. 51.
    Tian J, Atkinson MA, Clare-Salzler M, et al (1996) Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 183:1561Google Scholar
  52. 52.
    Tuohy VK, Lu Z, Sobel RA, Lauresen RA, Lees MB (1989) Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J Immunol 142:1523Google Scholar
  53. 53.
    Vainiene M, Gold DP, Celnik B, Hashim GA, Vandenbark AA, Offner H (1996) Natural immunodominant and EAE-protective determinants within the Lewis rat VB8.2 sequence include CDR2 and framework 3 idiotopes. J Neurosci Res 43:137Google Scholar
  54. 54.
    Vandenbark AA, Hashim G, Offner H (1989) Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 341:541Google Scholar
  55. 55.
    Vandenbark AA, Vainiene M, Celnik B, Hashim GA, Buenafe A, Offner H (1994) Definition of encephalitogenic and immunodominant epitopes of guinea pig myelin basic protein (Gp-BP) in Lewis rats tolerized neonatally with Gp-BP or Gp-BP peptides. J Immunol 153:852Google Scholar
  56. 56.
    Vandenbark AA, Celnik B, Vainiene M, Miller SD, Offner H (1995) Myelin antigen-coupled splenocytes suppress experimental autoimmune encephalomyelitis in Lewis rats through a partially reversible anergy mechanism. J Immunol 155:5861Google Scholar
  57. 57.
    Vandenbark AA, Hashim GA, Offner H (1996) T cell receptor peptides in treatment of autoimmune disease: rationale and potential. J Neurosci Res 43:391Google Scholar
  58. 58.
    Vandenbark AA, Chou YK, Whitham R, Mass M, Buenafe A, Liefeld D, Kavanagh D, Cooper S, Hashim GA, Offner H, Bourdette DN (1996) Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat Med 2:1109Google Scholar
  59. 59.
    Vandenbark AA, Chou YK, Bourdette DN, Whitham R, Offner H (1997) Immunogenicity is critical to the therapeutic application of T cell receptor peptide. Drug News Persp 10:341Google Scholar
  60. 60.
    Weinberg AD, Wyrick G, Celnik B, Vainiene M, Bakke A, Offner H, Vandenbark AA (1993) Lymphokine mRNA expression in the spinal cords of Lewis rats with EAE is mainly associated with a host recruited CD45R hi/CD4+ population during recovery. J Neuroimmunol 48:105Google Scholar
  61. 61.
    Weinberg AD, Wallin JJ, Jones RE, Sullivan TJ, Bourdette DN, Vandenbark AA, Offner H (1994) Target organ specific upregulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis. J Immunol 152:4712Google Scholar
  62. 62.
    Weiner HL, Friedman A, Miller A, et al (1994) Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 12:809Google Scholar
  63. 63.
    Whitacre CC, Bitar DM, Gienapp IE, Orosz CG (1991) Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J Immunol 147:2155Google Scholar
  64. 64.
    Windhagen A, Scholz C, Hollsberg P, Fukaura H, Sette A, Hafler DA (1995) Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 2:373Google Scholar
  65. 65.
    Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against α4/β1 integrin. Nature 356:63Google Scholar
  66. 66.
    Zhao M-L, Xia J-Q, Fritz RB (1993) Interleukin-3 and encephalitogenic activity of SJL/J myelin basic protein-specific T cell lines. J Neuroimmunol 43:69Google Scholar

Copyright information

© Springer-Verlag 1999

Authors and Affiliations

  • Halina Offner
    • 1
    • 2
  • Ray Jacobs
    • 1
  • Bruce F. BeboJr.
    • 1
    • 2
  • Arthur A. Vandenbark
    • 1
    • 2
    • 3
  1. 1.Department of Veterans Affairs, Neuroimmunology Research, R&D-31Oregon Health Sciences UniversityPortlandUSA
  2. 2.Departments of NeurologyOregon Health Sciences UniversityPortlandUSA
  3. 3.Molecular Microbiology and ImmunologyOregon Health Sciences UniversityPortlandUSA

Personalised recommendations